Patents by Inventor Marcela Cristina Corrêa de FREITAS

Marcela Cristina Corrêa de FREITAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for modifying human cell lines to produce factor VII
    Patent number: 11286503
    Abstract: A process for producing blood coagulation Factor VII in large scale in 3 human cell lines (HepG2, Sk-Hep, and HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allowed for the assertion that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest in a stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter proved to be able to produce rFVII more efficiently, which allows us to conclude that human cell lines are a great alternative to produce recombinant blood coagulation factors in large scale.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: March 29, 2022
    Inventors: Dimas Tadeu Covas, Marcela Cristina Corrêa de Freitas, Virginia Picanço e Castro, Kamilla Swiech
  • PROCESS FOR MODIFYING HUMAN CELL LINES TO PRODUCE FACTOR VII
    Publication number: 20200347406
    Abstract: A process for producing blood coagulation Factor VII in large scale in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allowed for the assertion that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest in a stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter proved to be able to produce rFVII more efficiently, which allows us to conclude that human cell lines are a great alternative to produce recombinant blood coagulation factors in large scale.
    Type: Application
    Filed: February 10, 2020
    Publication date: November 5, 2020
    Inventors: Dimas Tadeu COVAS, Marcela Cristina Corrêa de FREITAS, Virginia Picanço e CASTRO, Kamilla SWIECH
  • Method for modifying human cell lines to produce factor VII
    Patent number: 10590405
    Abstract: A process for producing blood coagulation Factor VII in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allow to assert that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest of stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter showed to be able to produce rFVII more efficiently, which allows to conclude that human cell lines are a great alternative for the production of recombinant blood coagulation factors.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 17, 2020
    Assignee: FUNDAÇÃO HEMOCENTRO DE RIBEIRÃO PRETO—FUNDHERP
    Inventors: Dimas Tadeu Covas, Marcela Cristina Corrêa de Freitas, Virginia Picanço e Castro, Kamilla Swiech
  • METHOD FOR PRODUCING BLOOD COAGULATION FACTOR VII, AND BLOOD COAGULATION FACTOR VII
    Publication number: 20180148705
    Abstract: A process for producing blood coagulation factor VII in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer. The murine line BHK-21 was used as control. The data allow to assert that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest of stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter showed to be able to produce rFVII more efficiently, which allows to conclude that human cell lines are a great alternative for the production of recombinant blood coagulation factors.
    Type: Application
    Filed: April 27, 2016
    Publication date: May 31, 2018
    Inventors: Dimas Tadeu COVAS, Marcela Cristina Corrêa de FREITAS, Virginia Picanço e CASTRO, Kamilla SWIECH